You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNabumetone
Accession NumberDB00461  (APRD01128)
TypeSmall Molecule
GroupsApproved
DescriptionNabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid family (which includes diclofenac). Marketed under the brand name Relafen, it has been shown to have a slightly lower risk of gastrointestinal side effects than most other non-selective NSAIDs.
Structure
Thumb
Synonyms
4-(6-Methoxy-2-naphthalenyl)-2-butanone
4-(6-Methoxy-2-naphthyl)-2-butanone
Nabumeton
Nabumetona
Nabumétone
Nabumetone
Nabumetonum
Relafen
External Identifiers
  • BRL 14777
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mylan-nabumetoneTablet500 mgOralMylan Pharmaceuticals Ulc2002-02-20Not applicableCanada
NabumetoneTablet500 mgOralSanis Health Inc2010-02-16Not applicableCanada
Nabumetone-500Tablet500 mgOralPro Doc Limitee2008-04-072010-07-13Canada
Nu-nabumetoneTablet500 mgOralNu Pharm IncNot applicableNot applicableCanada
PMS-nabumetoneTablet500 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-nabumetoneTablet750 mgOralPharmascience IncNot applicableNot applicableCanada
Relafen Tablets 500mgTablet500 mgOralGlaxosmithkline Inc1994-12-312006-02-13Canada
Relafen Tablets 750mgTablet750 mgOralGlaxosmithkline Inc1998-01-292006-02-13Canada
Sandoz NabumetoneTablet500 mgOralSandoz Canada Incorporated2002-02-212008-08-07Canada
Teva-nabumetoneTablet500 mgOralTeva Canada Limited2000-03-08Not applicableCanada
Teva-nabumetoneTablet750 mgOralTeva Canada Limited2000-05-18Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nabumetoneTablet500 mgOralApotex Inc1998-08-21Not applicableCanada
NabumetoneTablet750 mg/1OralMajor Pharmaceuticals2009-06-10Not applicableUs
NabumetoneTablet, film coated750 mg/1OralPhysicians Total Care, Inc.2002-12-04Not applicableUs
NabumetoneTablet, film coated500 mg/1OralAv Kare, Inc.2014-01-20Not applicableUs
NabumetoneTablet, film coated500 mg/1OralCarilion Materials Management2011-06-13Not applicableUs
NabumetoneTablet, film coated500 mg/1OralClinical Solutions Wholesale2011-06-13Not applicableUs
NabumetoneTablet, film coated500 mg/1OralActavis Pharma, Inc.2011-06-13Not applicableUs
NabumetoneTablet, film coated500 mg/1OralTeva Pharmaceuticals USA Inc2001-08-20Not applicableUs
NabumetoneTablet, film coated750 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-11-16Not applicableUs
NabumetoneTablet, film coated500 mg/1OralAidarex Pharmaceuticals LLC2011-06-13Not applicableUs
NabumetoneTablet, film coated500 mg/1Oralbryant ranch prepack2008-03-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralAmerican Health Packaging2010-10-012015-12-29Us
NabumetoneTablet, film coated750 mg/1OralA S Medication Solutions2008-03-012016-10-19Us
NabumetoneTablet, film coated750 mg/1OralGlenmark Pharmaceuticals Inc., Usa2008-03-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralLiberty Pharmaceuticals, Inc.2015-04-14Not applicableUs
NabumetoneTablet, film coated500 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
NabumetoneTablet500 mg/1OralBlenheim Pharmacal, Inc.2010-03-24Not applicableUs
NabumetoneTablet750 mg/1OralClinical Solutions Wholesale2011-06-13Not applicableUs
NabumetoneTablet, film coated750 mg/1OralMedsource Pharmaceuticals2008-03-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralH.J. Harkins Company, Inc.2008-03-01Not applicableUs
NabumetoneTablet750 mg/1OralLake Erie Medical DBA Quality Care Products LLC2002-02-25Not applicableUs
NabumetoneTablet, film coated500 mg/1OralDispensing Solutions, Inc.2008-03-01Not applicableUs
NabumetoneTablet, film coated750 mg/1OralMylan Pharmaceuticals Inc.2012-08-21Not applicableUs
NabumetoneTablet, film coated500 mg/1OralA S Medication Solutions2008-03-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-22Not applicableUs
NabumetoneTablet, film coated500 mg/1OralBlenheim Pharmacal, Inc.2010-06-11Not applicableUs
NabumetoneTablet, film coated500 mg/1OralCardinal Health2010-08-06Not applicableUs
NabumetoneTablet, film coated750 mg/1OralAv Kare, Inc.2014-01-20Not applicableUs
NabumetoneTablet, film coated500 mg/1OralLupin Pharmaceuticals, Inc.2012-08-27Not applicableUs
NabumetoneTablet500 mg/1OralREMEDYREPACK INC.2016-02-09Not applicableUs
NabumetoneTablet, film coated750 mg/1OralActavis Pharma, Inc.2011-06-13Not applicableUs
NabumetoneTablet, film coated750 mg/1OralTeva Pharmaceuticals USA Inc2001-09-26Not applicableUs
NabumetoneTablet, film coated500 mg/1OralUnit Dose Services2008-03-01Not applicableUs
NabumetoneTablet, film coated750 mg/1OralAidarex Pharmaceuticals LLC2008-03-01Not applicableUs
NabumetoneTablet, film coated750 mg/1Oralbryant ranch prepack2008-03-01Not applicableUs
NabumetoneTablet500 mg/1OralDr. Reddy's Laboratories Limited2015-08-10Not applicableUs
NabumetoneTablet, film coated750 mg/1OralDIRECT RX2015-01-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralMedsource Pharmaceuticals2008-03-01Not applicableUs
NabumetoneTablet500 mg/1OralAvera Mc Kennan Hospital2015-03-23Not applicableUs
NabumetoneTablet, film coated750 mg/1OralLiberty Pharmaceuticals, Inc.2015-04-14Not applicableUs
NabumetoneTablet, film coated750 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
NabumetoneTablet750 mg/1OralSTAT Rx USA LLC2003-01-24Not applicableUs
NabumetoneTablet, film coated750 mg/1OralH.J. Harkins Company, Inc.2008-03-01Not applicableUs
NabumetoneTablet, film coated750 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2008-03-01Not applicableUs
NabumetoneTablet500 mg/1OralAmerican Health Packaging2013-10-28Not applicableUs
NabumetoneTablet500 mg/1OralPar Pharmaceutical Inc2003-01-24Not applicableUs
NabumetoneTablet500 mg/1OralEon Labs, Inc.2002-02-25Not applicableUs
NabumetoneTablet, film coated750 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-22Not applicableUs
NabumetoneTablet, film coated500 mg/1OralBlenheim Pharmacal, Inc.2013-05-22Not applicableUs
NabumetoneTablet750 mg/1OralPd Rx Pharmaceuticals, Inc.2002-02-25Not applicableUs
NabumetoneTablet, film coated500 mg/1OralSTAT Rx USA LLC2008-03-01Not applicableUs
NabumetoneTablet, film coated750 mg/1OralLupin Pharmaceuticals, Inc.2012-08-27Not applicableUs
NabumetoneTablet, film coated500 mg/1OralImpax Generics2001-08-20Not applicableUs
NabumetoneTablet, film coated500 mg/1OralAv Pak2016-11-22Not applicableUs
NabumetoneTablet, film coated750 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-03-01Not applicableUs
NabumetoneTablet, film coated750 mg/1OralUnit Dose Services2008-03-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralRx Change Co.2014-11-13Not applicableUs
NabumetoneTablet500 mg/1OralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralDIRECT RX2015-01-01Not applicableUs
NabumetoneTablet750 mg/1OralDr. Reddy's Laboratories Limited2015-08-10Not applicableUs
NabumetoneTablet, film coated750 mg/1OralProficient Rx LP2011-06-13Not applicableUs
NabumetoneTablet500 mg/1OralREMEDYREPACK INC.2011-06-092016-10-13Us
NabumetoneTablet, film coated500 mg/1OralExelan Pharmaceuticals Inc.2015-04-14Not applicableUs
NabumetoneTablet, film coated500 mg/1OralA S Medication Solutions2011-06-13Not applicableUs
NabumetoneTablet, film coated500 mg/1OralRebel Distributors Corp.2008-03-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralPhysicians Total Care, Inc.2003-09-15Not applicableUs
NabumetoneTablet, film coated500 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-06-13Not applicableUs
NabumetoneTablet, film coated750 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
NabumetoneTablet750 mg/1OralPar Pharmaceutical Inc2003-01-24Not applicableUs
NabumetoneTablet750 mg/1OralEon Labs, Inc.2002-02-25Not applicableUs
NabumetoneTablet500 mg/1OralMajor Pharmaceuticals2009-06-10Not applicableUs
NabumetoneTablet, film coated750 mg/1OralAv Pak2016-11-22Not applicableUs
NabumetoneTablet, film coated750 mg/1OralBlenheim Pharmacal, Inc.2013-10-08Not applicableUs
NabumetoneTablet500 mg/1OralPd Rx Pharmaceuticals, Inc.2002-02-25Not applicableUs
NabumetoneTablet, film coated750 mg/1OralSTAT Rx USA LLC2008-03-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralGlenmark Pharmaceuticals Inc., Usa2008-03-01Not applicableUs
NabumetoneTablet, film coated750 mg/1OralImpax Generics2001-09-26Not applicableUs
NabumetoneTablet, film coated500 mg/1OralMylan Pharmaceuticals Inc.2012-08-21Not applicableUs
NabumetoneTablet, film coated750 mg/1OralProficient Rx LP2008-03-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-03-01Not applicableUs
NabumetoneTablet, film coated750 mg/1OralNorthwind Pharmaceuticals, LLC2014-10-28Not applicableUs
NabumetoneTablet, film coated750 mg/1OralRx Change Co.2014-11-13Not applicableUs
NabumetoneTablet750 mg/1OralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralProficient Rx LP2008-03-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-08-26Not applicableUs
NabumetoneTablet, film coated750 mg/1OralExelan Pharmaceuticals Inc.2015-04-14Not applicableUs
NabumetoneTablet, film coated750 mg/1OralA S Medication Solutions2011-06-13Not applicableUs
NabumetoneTablet, film coated750 mg/1OralRebel Distributors Corp.2008-03-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArthaxanSmithKline Beecham (Germany; discontinued)
BalmoxBeecham (Portugal), Meda (Switzerland)
DolsinalFerrer (Spain; discontinued)
ListranUriach (Spain)
MebutanMeda (Netherlands)
NabuserGeymonat (Italy)
RelafenGlaxoSmithKline (Canada, USA; discontinued)
RelifMeda (Spain)
RelifenSanwa (Japan), GSK (South Africa)
RelifexMeda (Czeck Republic, Denmark, Finland, Germany, Greece, Hungary, Ireland, Italy, Norway, Sweden, United Kingdom), GSK (Israel, Mexico, Poland, Thailand, Turkey), SmithKline Beecham (Philippines)
Brand mixturesNot Available
SaltsNot Available
Categories
UNIILW0TIW155Z
CAS number42924-53-8
WeightAverage: 228.2863
Monoisotopic: 228.115029756
Chemical FormulaC15H16O2
InChI KeyBLXXJMDCKKHMKV-UHFFFAOYSA-N
InChI
InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3
IUPAC Name
4-(6-methoxynaphthalen-2-yl)butan-2-one
SMILES
COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
Pharmacology
IndicationFor acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Structured Indications
PharmacodynamicsNabumetone is a naphthylalkanone. Is is a non-selective prostaglandin G/H synthase (a.k.a. cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to prostaglandin G2 and prostaglandin G2 to prostaglandin H2. Prostaglandin H2 is the precursor to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. The parent compound is a prodrug that undergoes hepatic biotransformation to the active compound, 6-methoxy-2-naphthylacetic acid (6MNA). The analgesic, antipyretic and anti-inflammatory effects of NSAIDs occur as a result of decreased prostaglandin synthesis.
Mechanism of actionThe parent compound is a prodrug, which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), that is a potent inhibitor of prostaglandin synthesis, most likely through binding to the COX-2 and COX-1 receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract. Coadministration of food increases the rate of absorption and subsequent appearance of 6MNA (the active metabolite) in the plasma but does not affect the extent of conversion of nabumetone into 6MNA.
Volume of distributionNot Available
Protein bindingThe active metabolite, 6MNA, is more than 99% bound to plasma proteins.
Metabolism

Undergoes rapid biotransformation to the principal active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine.

SubstrateEnzymesProduct
Nabumetone
Not Available
6-methoxy-2-naphthylacetic acidDetails
Route of eliminationApproximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine.
Half lifeApproximately 23 hours for the active metabolite, 6MNA. Increased in patients with renal insufficiency.
Clearance
  • 20 – 30 mL/min
ToxicityThe one overdose occurred in a 17-year-old female patient who had a history of abdominal pain and was hospitalized for increased abdominal pain following ingestion of 30 nabumetone tablets (15 grams total). Stools were negative for occult blood and there was no fall in serum hemoglobin concentration. The patient had no other symptoms.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nabumetone Action PathwayDrug actionSMP00114
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Nabumetone is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Nabumetone is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Nabumetone is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Nabumetone is combined with 5-androstenedione.Experimental, Illicit
AbciximabNabumetone may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Nabumetone can be increased when it is combined with Abiraterone.Approved
AcebutololNabumetone may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Nabumetone.Approved
AcenocoumarolNabumetone may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Nabumetone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Nabumetone.Approved, Vet Approved
AclarubicinNabumetone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Nabumetone.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Nabumetone is combined with Alendronic acid.Approved
AliskirenNabumetone may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololNabumetone may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Nabumetone.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Amcinonide.Approved
AmikacinNabumetone may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideNabumetone may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinNabumetone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodNabumetone may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Nabumetone is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Nabumetone.Investigational
annamycinNabumetone may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nabumetone.Approved
Antithrombin III humanNabumetone may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Nabumetone may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanNabumetone may increase the anticoagulant activities of Apixaban.Approved
ApramycinNabumetone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Nabumetone.Approved, Investigational
ArbekacinNabumetone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinNabumetone may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanNabumetone may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololNabumetone may decrease the antihypertensive activities of Arotinolol.Approved
AtenololNabumetone may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Nabumetone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nabumetone.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nabumetone.Approved
AzithromycinThe metabolism of Nabumetone can be decreased when combined with Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Nabumetone.Approved, Investigational
BazedoxifeneNabumetone may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminNabumetone may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNabumetone may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nabumetone.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nabumetone.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Nabumetone.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nabumetone.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Betamethasone.Approved, Vet Approved
BetaxololNabumetone may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Nabumetone.Investigational
BevantololNabumetone may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nabumetone.Approved, Investigational
BisoprololNabumetone may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNabumetone may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololNabumetone may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Nabumetone can be decreased when combined with Bortezomib.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nabumetone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Nabumetone.Investigational
BucindololNabumetone may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Budesonide.Approved
BufuralolNabumetone may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideNabumetone may decrease the diuretic activities of Bumetanide.Approved
BupranololNabumetone may decrease the antihypertensive activities of Bupranolol.Approved
CaffeineThe metabolism of Nabumetone can be decreased when combined with Caffeine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nabumetone.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nabumetone.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nabumetone.Approved
CarbamazepineThe metabolism of Nabumetone can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nabumetone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Nabumetone.Approved, Vet Approved, Withdrawn
CarteololNabumetone may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNabumetone may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nabumetone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Celecoxib.Approved, Investigational
CeliprololNabumetone may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinNabumetone may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nabumetone.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nabumetone.Approved, Vet Approved
ChlorotrianiseneNabumetone may increase the thrombogenic activities of Chlorotrianisene.Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nabumetone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nabumetone.Approved
CinoxacinNabumetone may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinNabumetone may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Nabumetone.Approved
Citric AcidNabumetone may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Nabumetone.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Nabumetone.Vet Approved
ClotrimazoleThe metabolism of Nabumetone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensNabumetone may increase the thrombogenic activities of Conjugated Equine Estrogens.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Nabumetone.Investigational
CyclosporineNabumetone may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Nabumetone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Nabumetone.Investigational
Dabigatran etexilateNabumetone may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinNabumetone may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNabumetone may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Nabumetone.Investigational
DaunorubicinNabumetone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Nabumetone is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Nabumetone is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinNabumetone may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Nabumetone.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nabumetone.Approved
DextranNabumetone may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Nabumetone may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Nabumetone may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Nabumetone may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nabumetone.Approved, Vet Approved
DicoumarolNabumetone may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolNabumetone may increase the thrombogenic activities of Dienestrol.Approved
DiethylstilbestrolNabumetone may increase the thrombogenic activities of Diethylstilbestrol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Nabumetone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nabumetone.Approved
DihydrostreptomycinNabumetone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Nabumetone.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nabumetone.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nabumetone.Approved
DoxorubicinNabumetone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneNabumetone may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Nabumetone.Approved
DuloxetineDuloxetine may increase the antiplatelet activities of Nabumetone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Nabumetone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Nabumetone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Nabumetone.Investigational
Edetic AcidNabumetone may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanNabumetone may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nabumetone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nabumetone.Approved
EnoxacinNabumetone may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinNabumetone may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Nabumetone.Approved
EpirubicinNabumetone may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneNabumetone may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nabumetone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nabumetone.Approved
EquileninThe risk or severity of adverse effects can be increased when Nabumetone is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Nabumetone is combined with Equilin.Approved
EscitalopramEscitalopram may increase the antiplatelet activities of Nabumetone.Approved, Investigational
EsmololNabumetone may decrease the antihypertensive activities of Esmolol.Approved
EstradiolNabumetone may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
EstriolNabumetone may increase the thrombogenic activities of Estriol.Approved, Vet Approved
EstroneNabumetone may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Estrone sulfate.Approved
Etacrynic acidNabumetone may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Nabumetone.Approved, Investigational
Ethinyl EstradiolNabumetone may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateNabumetone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Nabumetone.Approved
EtoperidoneEtoperidone may increase the antiplatelet activities of Nabumetone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Nabumetone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Nabumetone.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Nabumetone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nabumetone.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Nabumetone.Vet Approved
FleroxacinNabumetone may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nabumetone.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Nabumetone is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fludrocortisone.Approved
FluindioneNabumetone may increase the anticoagulant activities of Fluindione.Investigational
FlumequineNabumetone may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Nabumetone.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluorometholone.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Nabumetone.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Nabumetone.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nabumetone.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Nabumetone can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nabumetone.Approved, Nutraceutical, Vet Approved
FondaparinuxNabumetone may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumNabumetone may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Nabumetone.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nabumetone.Approved
FramycetinNabumetone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideNabumetone may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateNabumetone may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinNabumetone may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinNabumetone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Nabumetone.Approved, Withdrawn
GemifloxacinNabumetone may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNabumetone may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinNabumetone may increase the thrombogenic activities of Genistein.Investigational
GentamicinNabumetone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANabumetone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinNabumetone may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Nabumetone is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Nabumetone is combined with HE3286.Investigational
HeparinNabumetone may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolNabumetone may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Nabumetone.Investigational
HirulogNabumetone may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Nabumetone.Investigational
HydralazineNabumetone may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nabumetone.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nabumetone.Approved
Hygromycin BNabumetone may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nabumetone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Nabumetone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Nabumetone.Approved
IdarubicinNabumetone may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxNabumetone may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nabumetone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nabumetone.Investigational
IndalpineIndalpine may increase the antiplatelet activities of Nabumetone.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nabumetone.Approved
IndenololNabumetone may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nabumetone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Nabumetone.Withdrawn
INNO-206Nabumetone may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nabumetone.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Nabumetone.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Nabumetone is combined with Istaroxime.Investigational
KanamycinNabumetone may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Nabumetone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nabumetone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nabumetone.Approved
LabetalolNabumetone may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nabumetone.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Nabumetone.Approved, Investigational
LepirudinNabumetone may increase the anticoagulant activities of Lepirudin.Approved
LevobunololNabumetone may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNabumetone may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Nabumetone.Approved
LidocaineThe metabolism of Nabumetone can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Nabumetone.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nabumetone.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Nabumetone.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Nabumetone.Approved
LomefloxacinNabumetone may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Nabumetone.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nabumetone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Nabumetone.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nabumetone.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Nabumetone.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nabumetone.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nabumetone.Approved
ME-609The risk or severity of adverse effects can be increased when Nabumetone is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nabumetone.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nabumetone.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Nabumetone is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nabumetone.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Nabumetone.Approved
MestranolNabumetone may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Nabumetone.Withdrawn
MethallenestrilNabumetone may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nabumetone.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nabumetone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNabumetone may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nabumetone.Approved
MetoprololNabumetone may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideNabumetone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe metabolism of Nabumetone can be decreased when combined with Mexiletine.Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Nabumetone.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nabumetone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Nabumetone.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nabumetone.Approved
MometasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nabumetone.Approved
MoxifloxacinNabumetone may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nabumetone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nabumetone.Approved
NadololNabumetone may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNabumetone may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Nabumetone.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nabumetone.Approved
Nalidixic AcidNabumetone may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Nabumetone.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Nabumetone is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Nabumetone.Investigational
NeamineNabumetone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneNefazodone may increase the antiplatelet activities of Nabumetone.Approved, Withdrawn
NemonoxacinNabumetone may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinNabumetone may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Nabumetone.Approved
NetilmicinNabumetone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NevirapineThe metabolism of Nabumetone can be decreased when combined with Nevirapine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nabumetone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nabumetone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Nabumetone.Investigational
NorfloxacinNabumetone may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinNabumetone may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nabumetone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nabumetone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nabumetone.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Nabumetone.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Nabumetone.Vet Approved
OsimertinibThe serum concentration of Nabumetone can be decreased when it is combined with Osimertinib.Approved
OtamixabanNabumetone may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nabumetone.Approved
OxprenololNabumetone may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nabumetone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Parecoxib.Approved
ParomomycinNabumetone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Nabumetone.Approved, Investigational
PazufloxacinNabumetone may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNabumetone may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Nabumetone can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololNabumetone may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateNabumetone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nabumetone.Approved
PhenindioneNabumetone may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Nabumetone can be increased when combined with Phenobarbital.Approved
PhenprocoumonNabumetone may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nabumetone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nabumetone.Approved, Investigational
PindololNabumetone may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinNabumetone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideNabumetone may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Nabumetone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nabumetone.Approved, Investigational
PlicamycinNabumetone may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
Polyestradiol phosphateNabumetone may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nabumetone.Approved
PractololNabumetone may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Nabumetone.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Nabumetone can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Nabumetone can be increased when it is combined with Probenecid.Approved
PromestrieneNabumetone may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Nabumetone.Approved
PropranololNabumetone may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Nabumetone.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Nabumetone.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Nabumetone.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Nabumetone.Vet Approved
Protein CNabumetone may increase the anticoagulant activities of Protein C.Approved
Protein S humanNabumetone may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNabumetone may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinNabumetone may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Nabumetone.Investigational
PuromycinNabumetone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nabumetone.Approved, Investigational
QuinestrolNabumetone may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nabumetone.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nabumetone.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nabumetone.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nabumetone.Experimental, Investigational
ReviparinNabumetone may increase the anticoagulant activities of Reviparin.Approved
RibostamycinNabumetone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Nabumetone can be increased when combined with Rifampicin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Risedronate.Approved, Investigational
RivaroxabanNabumetone may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe metabolism of Nabumetone can be decreased when combined with Ropinirole.Approved, Investigational
RosoxacinNabumetone may increase the neuroexcitatory activities of Rosoxacin.Approved
S EquolNabumetone may increase the thrombogenic activities of S Equol.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nabumetone.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Nabumetone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nabumetone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Nabumetone.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nabumetone.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Nabumetone.Investigational
SecoisolariciresinolNabumetone may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Nabumetone.Approved, Investigational
SertralineSertraline may increase the antiplatelet activities of Nabumetone.Approved
SimeprevirThe metabolism of Nabumetone can be decreased when combined with Simeprevir.Approved
SisomicinNabumetone may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolNabumetone may decrease the antihypertensive activities of Sotalol.Approved
SP1049CNabumetone may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinNabumetone may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinNabumetone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Nabumetone.Approved
SpironolactoneNabumetone may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Nabumetone.Investigational
StreptomycinNabumetone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinNabumetone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nabumetone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Nabumetone.Approved
SulodexideNabumetone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Nabumetone.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Nabumetone.Approved, Withdrawn
Synthetic Conjugated Estrogens, ANabumetone may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BNabumetone may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusNabumetone may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Nabumetone.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Nabumetone.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nabumetone.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nabumetone.Approved, Investigational
TemafloxacinNabumetone may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Nabumetone.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nabumetone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Nabumetone.Vet Approved
TeriflunomideThe serum concentration of Nabumetone can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Nabumetone can be decreased when combined with Theophylline.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nabumetone.Approved
TiboloneNabumetone may increase the thrombogenic activities of Tibolone.Approved
TiclopidineThe metabolism of Nabumetone can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tiludronate.Approved, Vet Approved
TimololNabumetone may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Nabumetone.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tixocortol.Approved
TobramycinNabumetone may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Nabumetone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nabumetone.Approved
TorasemideNabumetone may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nabumetone.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Nabumetone.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nabumetone.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nabumetone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNabumetone may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nabumetone.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Nabumetone.Approved
TrovafloxacinNabumetone may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nabumetone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinNabumetone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nabumetone.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Nabumetone.Approved
VemurafenibThe serum concentration of Nabumetone can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Nabumetone.Approved
WarfarinNabumetone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNabumetone may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Nabumetone may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nabumetone.Approved
ZeranolNabumetone may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Nabumetone.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Nabumetone.Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Nabumetone is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nabumetone.Withdrawn
ZorubicinNabumetone may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Avoid alcohol.
  • Take with food for faster absorption.
References
Synthesis Reference

Brian F. Becnel, Mahmood Sabahi, Kevin J. Theriot, “Production of nabumetone or precursors thereof.” U.S. Patent US5907069, issued December, 1985.

US5907069
General ReferencesNot Available
External Links
ATC CodesM01AX01
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (322 KB)
MSDSDownload (29.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9401
Caco-2 permeable+0.9049
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.5653
P-glycoprotein inhibitor IIInhibitor0.5656
Renal organic cation transporterNon-inhibitor0.7143
CYP450 2C9 substrateNon-substrate0.7664
CYP450 2D6 substrateNon-substrate0.7329
CYP450 3A4 substrateSubstrate0.614
CYP450 1A2 substrateInhibitor0.959
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8591
CYP450 3A4 inhibitorNon-inhibitor0.8235
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6443
Ames testNon AMES toxic0.8942
CarcinogenicityNon-carcinogens0.8745
BiodegradationNot ready biodegradable0.8489
Rat acute toxicity1.7384 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7536
hERG inhibition (predictor II)Non-inhibitor0.8059
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis elizabeth llc
  • Copley pharmaceutical inc
  • Dr reddys laboratories ltd
  • Invagen pharmaceuticals inc
  • Matrix laboratories ltd
  • Par pharmaceutical
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Smithkline beecham corp dba glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
TabletOral500 mg
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral750 mg/1
TabletOral750 mg
Prices
Unit descriptionCostUnit
Relafen 750 mg tablet2.91USD tablet
Relafen 500 mg tablet2.82USD tablet
Nabumetone 750 mg tablet1.56USD tablet
Nabumetone 500 mg tablet1.32USD tablet
Apo-Nabumetone 500 mg Tablet0.39USD tablet
Mylan-Nabumetone 500 mg Tablet0.39USD tablet
Novo-Nabumetone 500 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPractically insolubleNot Available
logP3.08ADLARD,M ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00193 mg/mLALOGPS
logP3.41ALOGPS
logP3.22ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)19.59ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area26.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity68.43 m3·mol-1ChemAxon
Polarizability26.17 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthalenes
Sub ClassNot Available
Direct ParentNaphthalenes
Alternative Parents
Substituents
  • Naphthalene
  • Anisole
  • Alkyl aryl ether
  • Ketone
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22. [PubMed:11153163 ]
  2. Roy HK, Karolski WJ, Ratashak A: Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int J Cancer. 2001 May 15;92(4):609-15. [PubMed:11304699 ]
  3. van Kraaij DJ, Hovestad-Witterland AH, de Metz M, Vollaard EJ: A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. Br J Clin Pharmacol. 2002 Jun;53(6):644-7. [PubMed:12047490 ]
  4. Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung KA, Ekbom A: Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs. 2004;64(20):2315-43; discussion 2344-5. [PubMed:15456329 ]
  5. Elliott SN, McKnight W, Cirino G, Wallace JL: A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 1995 Aug;109(2):524-30. [PubMed:7615202 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Giuliano F, Ferraz JG, Pereira R, de Nucci G, Warner TD: Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol. 2001 Aug 24;426(1-2):95-103. [PubMed:11525777 ]
  2. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I: Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006 Feb;4(2):196-202. [PubMed:16469680 ]
  3. Cipollone F, Ganci A, Panara MR, Greco A, Cuccurullo F, Patrono C, Patrignani P: Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther. 1995 Sep;58(3):335-41. [PubMed:7554708 ]
  4. Bensen W, Zizzo A: Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis. Can Fam Physician. 1998 Jan;44:101-2, 105-7. [PubMed:9481468 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Saleh TS, Calixto JB, Medeiros YS: Effects of anti-inflammatory drugs upon nitrate and myeloperoxidase levels in the mouse pleurisy induced by carrageenan. Peptides. 1999;20(8):949-56. [PubMed:10503773 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Turpeinen M, Hofmann U, Klein K, Murdter T, Schwab M, Zanger UM: A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos. 2009 May;37(5):1017-24. doi: 10.1124/dmd.108.025700. Epub 2009 Feb 9. [PubMed:19204080 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23